Resumo

LAMI CASAUS, Leonardo; ARBESU MICHELENA, María Antonieta; SARMIENTO, Sofía Alsina  e  BRITO IGLESIA, Rosario. Appearance of febrile neutropenia episodes after cytostatic therapy on Oncology patients. Rev Cubana Farm [online]. 2009, vol.43, n.4, pp. 68-73. ISSN 1561-2988.

Treatment of oncology patient using cytotoxic drugs has the neutropenia and its infectious complications as the commonest dose-limiting toxicity. Its appearance provokes dose delays and reduction during post-chemotherapy cycles, as well as the quality of life deterioration of patients. Oncology Medicine Group including the Pharmacy Service carried out a study to analyze the appearance of febrile neutropenia after cytotoxic therapy administration, and the presence of other factors that may to increase the risk to these reactions. A total of 42 patients were studied admitted with febrile neutropenia after above therapy from February to August, 2007. Biomedical variables from included patient group were achieved and the previously applied cytostatic therapy. The prevalent age-group was those patients aged over 50 and predominance of male sex and advanced stages with associated affections. The more frequent tumor locations were in breast, lung, and non-Hodgkin lymphoma. The cytostatic agent more used in cases of febrile neutropenia was Adriamycin (71.4 %) followed by Cyclophosphamide (52.4 %). The factors more associated with febrile neutropenia appearance were: Anthracycline chemotherapy, age over 50, advanced stages, and presence of associated diseases.

Palavras-chave : Febrile neutropenia; cytostatic agents; adverse reactions.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )